JC virus or extended interval dosing? More data are needed

Abstract

Get full access to this article

View all access options for this article.

References

Dalla Costa

Leocani

Pisa

, et al. Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres. Mult Scler J. Epub ahead of print 14 June 2024. DOI: 10.1177/13524585241260977.

Foley

Defer

Ryerson

, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): A randomised, controlled, open-label, phase 3b trial. Lancet Neurol 2022; 21(7): 608–619.